ArticleACS omega2025
Dual-Site Chemically Engineered MNAzymes for One-Pot Isothermal Detection of MicroRNAs.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sensitive detection of microRNAs (miRNAs) remains challenging due to their low abundance and sequence similarity. Conventional DNAzyme- and multicomponent nucleic acid enzyme (MNAzyme)-based assays are enzyme-free but often limited by poor catalytic turnover. Here, we present a dual-site chemically engineered MNAzyme platform that integrates xeno-nucleic acid modification within the catalytic core and locked nucleic acid substitution within the target-binding arms to synergistically enhance catalytic and recognition efficiency. The resulting hybrid, termed LXMz, exhibits an ∼760-fold improvement in catalytic rate and an ∼450-fold increase in sensitivity relative to the unmodified MNAzyme. Under isothermal, one-pot conditions, LXMz achieves the quantitative detection of miR-92a with a limit of detection of 2 pM while maintaining single-base specificity. By combining catalytic enhancement and hybridization stabilization within a unified molecular design, this study establishes a new chemical engineering principle for constructing robust, enzyme-free biosensors. The LXMz framework provides a versatile and sensitive platform for miRNA analysis and holds promise for liquid biopsy and point-of-care diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.